<DOC>
	<DOCNO>NCT02748161</DOCNO>
	<brief_summary>Patients enrol study diagnose hepatocellular carcinoma ( HCC ) schedule procedure call drug-eluting bead trans-arterial chemoembolization ( DEB-TACE ) . During DEB-TACE procedure , small bead mixed chemotherapy drug , doxorubicin , deliver tumor arterial catheter . The DEB-TACE procedure allow treatment deliver directly liver . It also cause arterial embolization , process blood vessel block . Treatment HCC use DEB-TACE may help delay tumor progression downstage ( decrease size ) cancer order meet criterion may allow patient become candidate liver transplantation . The purpose study compare tumor response medical outcome patient undergo DEB-TACE standard endhole catheter versus Surefire® Infusion System .</brief_summary>
	<brief_title>DEB-TACE Hepatocellular Carcinoma</brief_title>
	<detailed_description>Conventional transarterial chemoembolization lipiodol/doxorubicin ( cTACE ) know prolong survival compare supportive therapy certain patient unresectable HCC , include patient unilateral portal vein invasion ( PVI ) . TACE doxorubicin-eluting bead ( DEB-TACE ) relatively new modality associate favorable systemic doxorubicin exposure/toxicity liver-specific toxicity compare cTACE study document safety efficacy . DEB-TACE currently utilize : ( 1 ) patient unresectable HCC ; ( 2 ) patient meet Milan Criteria currently liver transplantation list ; ( 3 ) downstaging patient Milan Criteria possible liver transplantation . The big challenge procedure inability actually quantify embolization real-time setting provide immediate feedback operator . Although various method , perfusion analysis CT MRI , describe , require advanced imaging equipment/capabilities , extensive post processing analysis , create challenging workflow . Currently best result occur dose deliver highly targeted manner tumor . Dense accumulation embolic spheres lipiodol tumor document CT show improved outcome . However , standard endhole catheter achieve maximum delivery embolic agent limit development stasis subsequent non-target injury . As DEB-TACE perform endhole catheter either stasis substasis endpoint . The current methodology extremely subjective , lack quantifiable endpoint , result various degree embolization patient . Often result repeat procedure progression tumor . Recently , FDA clearance new anti-reflux catheter , Surefire® Infusion System ( SIS , Westminster , CO ) . The current design expandable tip collapse forward flow , dynamically seal vessel reversal flow , analogous valve . SIS , expandable tip microcatheter , demonstrate clinically cause slight decrease intra-arterial pressure antegrade , downstream , vascular compartment . Although device design primarily prevent retrograde reflux embolic agent , downstream blood pressure reduction may serve biomarker quantify embolization . The goal develop method : ( 1 ) allow maximum delivery embolic spheres tumor tissue stasis without reflux ; ( 2 ) enables direct real time numerical quantification degree embolization ; ( 3 ) provide intra-procedural functional parameter could use guide optimal therapeutic endpoint time treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Patients age 18 year old diagnosis HCC currently evaluate liver transplantation . Meets Milan Criteria : single tumor ≤ 5 cm , maximum 3 total tumor ≤ 3 cm AND/OR , meet UCSF criterion : single lesion &lt; 6.5 cm diameter 23 lesion &lt; 4.5 cm total tumor diameter &lt; 8 cm . No portal invasion extrahepatic spread image . Child 's Class A B . No previous chemotherapy , radiotherapy transarterial embolization ( without chemotherapy ) . An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , preserve liver function ( ChildPugh Class A B ) . Has discrete hepatic artery feed tumor diameter vessel great 1.5 mm . Advanced bilirubin level great 3 mg/dl , AST ALT great 5 time upper limit normal great 250 U/l . Advanced tumoral disease ( vascular invasion extrahepatic spread , portal vein thrombosis bland malignant origin , diffuse HCC , define 50 % liver involvement ) . Contraindications doxorubicin administration . Child 's Class C. Vessels provide flow tumor le 1.5 mm diameter . Patient known history contraindicate contrast dye iodine safely control via antihistamine , steroid , agent . Unable provide inform consent . Women pregnant currently breast feed . Women childbearing potential use acceptable method birth control ( e.g. , pill , patch , IUD , ring , condom , sponge , foam ) . Exclusion criterion include portal vein thrombosis bland malignant origin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>DEB-TACE</keyword>
	<keyword>QED</keyword>
</DOC>